Azenta (NASDAQ:AZTA) Sets Higher Revenue Target After Fiscal Results and Gene Synthesis Investments

Aditi Sarkar

12 November 2026 04:53 PM AEDT

Azenta (NASDAQ:AZTA) Sets Higher Revenue Target After Fiscal Results and Gene Synthesis Investments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Azenta reported fiscal fourth-quarter continuing-operations Revenue of USD 167 mn, rising 5% year over year.
Full-year fiscal 2026 continuing-operations revenue reached USD 622 mn, also increasing 5%.
The company announced a licensing arrangement with Elegen and the Acquisition of SynPlexity in October.
Azenta forecast fiscal 2027 continuing-operations revenue between USD 648 mn and USD 660 mn.

A new fiscal year is beginning with a larger revenue target and investments in gene synthesis capabilities for Azenta, Inc. (NASDAQ:AZTA). The life-sciences services provider reported 5% fourth-quarter revenue growth on November 10 and outlined expected fiscal 2027 expansion alongside its GENEWIZ technology initiatives.

Quarterly Results Establish the Baseline

Azenta reported USD 167 mn in fiscal fourth-quarter 2026 revenue from continuing operations, compared with USD 159 mn in the prior-year quarter. Reported growth was 5%, while organic growth was 2%. The company recorded adjusted Diluted Earnings per Share from continuing operations of USD 0.28, compared with USD 0.21 a year earlier. Adjusted EBITDA for the quarter was approximately USD 19.4 mn.

Two Operating Segments Tell the Full-Year Story

Fiscal 2026 continuing-operations revenue reached USD 622 mn, increasing 5% on a reported basis and 2% organically. Sample Management Solutions generated USD 344 mn, up 6%, while Multiomics generated USD 277 mn, up 3%. The company reported an annual GAAP operating loss influenced by a noncash Goodwill Impairment charge. Cash, cash equivalents, restricted cash and marketable securities totalled approximately USD 506 mn at September 30.

Gene Synthesis Investments Add a Strategic Focus

On October 30, Azenta announced an exclusive licensing agreement with Elegen and the acquisition of SynPlexity to develop the next stage of its GENEWIZ gene synthesis capabilities. The initiatives relate to high-throughput discovery workflows and expanded technology offerings. Management expects fiscal 2027 to include integration, scale-up and commercialisation activity connected to these arrangements.

Fiscal 2027 Guidance Moves Above the Latest Year

Azenta forecast fiscal 2027 revenue from continuing operations of approximately USD 648 mn to USD 660 mn. It expects organic revenue growth of 3% to 5% and adjusted EBITDA Margin expansion of 200–250 basis points year over year, including expected dilution associated with gene synthesis investments. Those objectives remain forward-looking. Execution in Sample Management Solutions and Multiomics will determine how closely realised performance tracks the guidance.

Stock Price Information: Azenta shares traded at USD 48.90, up 20.80%, in the November 11, 2026 market figures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.